Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
264500 269000 261500 265500 265500 Last
350960 545001 604854 557630 488250 Volume
-0.94% +1.70% -2.79% +1.53% 0.00% Change
Financials
Sales 2021 2 341 B 2,10 B 2,10 B
Net income 2021 762 B 0,68 B 0,68 B
Net cash position 2021 634 B 0,57 B 0,57 B
P/E ratio 2021 48,0x
Yield 2021 0,00%
Sales 2022 2 777 B 2,49 B 2,49 B
Net income 2022 861 B 0,77 B 0,77 B
Net cash position 2022 1 145 B 1,03 B 1,03 B
P/E ratio 2022 42,5x
Yield 2022 0,01%
Capitalization 36 266 B 32 458 M 32 494 M
EV / Sales 2021 15,2x
EV / Sales 2022 12,6x
Nbr of Employees 2 072
Free-Float 69,0%
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical... 
More about the company
Ratings of Celltrion, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CELLTRION, INC.
06/07MARKET CHATTER : Celltrion to Invest $47 Million in British Biotech Firm Iksuda ..
MT
05/21Celltrion's Breast Cancer Drug Captures 47% Share of Japan Market
MT
05/07EU regulator begins real-time review of GSK-Vir COVID-19 antibody drug
RE
05/03S.Korean stocks fall for 5th day on worries over partial lifting of short-sel..
RE
04/20COVID Quick Test by South Korea's Celltrion and Humasis Gets US FDA Approval ..
MT
04/01CELLTRIONá : Healthcare receives positive CHMP opinion for subcutaneous formulat..
AQ
03/25MARKET CHATTER : South Korea's Pharma Exports Surge 23% in 2020
MT
03/09MARKET CHATTER : Celltrion Initiates Clinical Trials for Heart Condition Treatme..
MT
03/03CELLTRIONá : EMA review of regdanvimab for COVID-19 to support national decision..
AQ
03/03S.Korean shares end higher as U.S. yields retreat, China policy anxiety eases
RE
02/26EU regulator advises use of Regeneron antibody cocktail for COVID-19
RE
02/25CELLTRIONá : EMA starts rolling review of Celltrion antibody regdanvimab for COV..
AQ
02/05Enthusiasm Fades for Covid-19 Antibody Treatments in South Korea
DJ
02/03S.Korea regulator extends ban on short-selling of stocks to May 2
RE
02/01S.Korea shares jumps most in 3 wks on upbeat trade data, fading volatility wo..
RE
More news
News in other languages on CELLTRION, INC.
05/07VACCINIá : Ue; aperti a dialogo, Usa sblocchi export (Stampa)
05/04MÄRKTE ASIEN/Erholt - Steigende Corona-Zahlen belasten in Taiwan
04/19MÄRKTE ASIEN/Überwiegend positive Stimmung an Börsen dank US-Rekorden
04/19MÄRKTE ASIEN/Positive Stimmung an den Börsen dank US-Rekorden
03/11CORONAVIRUS : L'EMA examine le traitement aux anticorps d'Eli Lilly
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 341 397,06 KRW
Last Close Price 265 500,00 KRW
Spread / Highest target 80,8%
Spread / Average Target 28,6%
Spread / Lowest Target -34,8%
EPS Revisions
Managers and Directors
NameTitle
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.-26.04%32 458
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
SEAGEN INC.-10.60%28 416
HANGZHOU TIGERMED CONSULTING CO., LTD13.85%24 128